Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the ...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
According to the Merriam-Webster Online Dictio-nary, a biomarker is ‘a distinctive biological or bio...
New biomarkers are being evaluated for their ability to advance the management of patients with hear...
Cardiovascular disease (CVD) remains a global health concern of paramount significance, claiming mil...
Cardiac diseases are mainly caused by malfunction of or injuries to the hearts. Although significan...
The majority of day-to-day clinical decision making is guided by the laboratory measurement of a bio...
The approval of new heart failure (HF) therapies has slowed over the past two decades in part due to...
The emerging novel heart failure (HF) biomarkers have been shown to provide additional value for pro...
Biomarkers are essential tools in the practice of cardiology. They assist with diagnosis, prognosis,...
Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and ...
Heart failure (HF) is one of the major causes of morbidity and mortality worldwide and represents an...
Here we review the highlights of cardiovascular basic science in published in 2021 and early 2022 on...
Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early dete...
Heart failure (HF) is a clinical syndrome resulting from structural or functional abnormality of the...
In this thesis, three different approaches to study biomarkers (bioinformatics, animal models and cl...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
According to the Merriam-Webster Online Dictio-nary, a biomarker is ‘a distinctive biological or bio...
New biomarkers are being evaluated for their ability to advance the management of patients with hear...
Cardiovascular disease (CVD) remains a global health concern of paramount significance, claiming mil...
Cardiac diseases are mainly caused by malfunction of or injuries to the hearts. Although significan...
The majority of day-to-day clinical decision making is guided by the laboratory measurement of a bio...
The approval of new heart failure (HF) therapies has slowed over the past two decades in part due to...
The emerging novel heart failure (HF) biomarkers have been shown to provide additional value for pro...
Biomarkers are essential tools in the practice of cardiology. They assist with diagnosis, prognosis,...
Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and ...
Heart failure (HF) is one of the major causes of morbidity and mortality worldwide and represents an...
Here we review the highlights of cardiovascular basic science in published in 2021 and early 2022 on...
Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early dete...
Heart failure (HF) is a clinical syndrome resulting from structural or functional abnormality of the...
In this thesis, three different approaches to study biomarkers (bioinformatics, animal models and cl...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
According to the Merriam-Webster Online Dictio-nary, a biomarker is ‘a distinctive biological or bio...
New biomarkers are being evaluated for their ability to advance the management of patients with hear...